Literature DB >> 27431863

Alterations in P-Glycoprotein Expression and Function Between Macrophage Subsets.

Theodore J Cory1, Hui He2, Lee C Winchester3, Santosh Kumar4, Courtney V Fletcher3.   

Abstract

PURPOSE: Macrophages are an important cellular reservoir in HIV, and exist in two phenotypically dissimilar subsets, the pro-inflammatory M1 phenotype, and the anti-inflammatory M2 phenotype. The role of these two subsets is uncertain. We hypothesized that differences in drug efflux transporters exist between the subsets, which would result in altered intracellular drug concentrations between these cells.
METHODS: U937 monocytic cells were polarized to the M1 or M2 phenotype via treatment with interferon-gamma and LPS, or interleukins 4, 13, and LPS, respectively. PGP function was assessed with Hoechst 33342, and expression via western blotting. Intracellular lopinavir was assessed via LC-MS/MS. Data was confirmed with primary monocyte derived macrophages.
RESULTS: We observed significant differences in intracellular concentrations of lopinavir, a PGP substrate, with higher concentrations in M1 cells. PGP function and expression was higher in the M2 macrophages. These results were confirmed with primary monocyte derived macrophages.
CONCLUSIONS: This data shows that there are previously unreported differences in P-glycoprotein expression between macrophage subsets, and suggests that there may be differences for other transporters. These differences can play a role in intracellular drug concentrations in these cells, and may allow for low-level HIV replication.

Entities:  

Keywords:  Hoechst 33342; P-glycoprotein; alternatively activated macrophage; classically activated macrophage

Mesh:

Substances:

Year:  2016        PMID: 27431863      PMCID: PMC5042840          DOI: 10.1007/s11095-016-1998-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  41 in total

Review 1.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

2.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

3.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Authors:  Courtney V Fletcher; Kathryn Staskus; Stephen W Wietgrefe; Meghan Rothenberger; Cavan Reilly; Jeffrey G Chipman; Greg J Beilman; Alexander Khoruts; Ann Thorkelson; Thomas E Schmidt; Jodi Anderson; Katherine Perkey; Mario Stevenson; Alan S Perelson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

Review 4.  The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure.

Authors:  Jennifer H Campbell; Anna C Hearps; Genevieve E Martin; Kenneth C Williams; Suzanne M Crowe
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

5.  Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages.

Authors:  N Suh; T Honda; H J Finlay; A Barchowsky; C Williams; N E Benoit; Q W Xie; C Nathan; G W Gribble; M B Sporn
Journal:  Cancer Res       Date:  1998-02-15       Impact factor: 12.701

Review 6.  Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents.

Authors:  Ahcène Boumendjel; Hélène Baubichon-Cortay; Doriane Trompier; Thomas Perrotton; Attilio Di Pietro
Journal:  Med Res Rev       Date:  2005-07       Impact factor: 12.944

7.  Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism.

Authors:  Kari Ann Shirey; Leah E Cole; Achsah D Keegan; Stefanie N Vogel
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  New functional assay of P-glycoprotein activity using Hoechst 33342.

Authors:  Henrik Müller; Werner Klinkhammer; Christoph Globisch; Matthias U Kassack; Ilza K Pajeva; Michael Wiese
Journal:  Bioorg Med Chem       Date:  2007-08-21       Impact factor: 3.641

9.  Azithromycin alters macrophage phenotype.

Authors:  Brian S Murphy; Vidya Sundareshan; Theodore J Cory; Don Hayes; Michael I Anstead; David J Feola
Journal:  J Antimicrob Chemother       Date:  2008-01-29       Impact factor: 5.790

10.  Identification of novel transcriptional regulators involved in macrophage differentiation and activation in U937 cells.

Authors:  Young-Sook Baek; Stefan Haas; Holger Hackstein; Gregor Bein; Maria Hernandez-Santana; Hans Lehrach; Sascha Sauer; Harald Seitz
Journal:  BMC Immunol       Date:  2009-04-02       Impact factor: 3.615

View more
  16 in total

Review 1.  The dawn of precision medicine in HIV: state of the art of pharmacotherapy.

Authors:  Ying Mu; Sunitha Kodidela; Yujie Wang; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Pharmacother       Date:  2018-09-20       Impact factor: 3.889

2.  Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages.

Authors:  Liang Pang; Yihua Pei; Gozde Uzunalli; Hyesun Hyun; L Tiffany Lyle; Yoon Yeo
Journal:  Pharm Res       Date:  2019-03-11       Impact factor: 4.200

Review 3.  The Potential Role of Exosomal Proteins in Prostate Cancer.

Authors:  Shangzhi Feng; Kecheng Lou; Xiaofeng Zou; Junrong Zou; Guoxi Zhang
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

4.  P-glycoprotein multidrug transporter in inflammatory bowel diseases: More questions than answers.

Authors:  Elke Cario
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

5.  Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.

Authors:  Narasimha M Midde; Namita Sinha; Pradeep B Lukka; Bernd Meibohm; Santosh Kumar
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

6.  M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis.

Authors:  Susann Badmann; Sabine Heublein; Doris Mayr; Anna Reischer; Yue Liao; Thomas Kolben; Susanne Beyer; Anna Hester; Christine Zeder-Goess; Alexander Burges; Sven Mahner; Udo Jeschke; Fabian Trillsch; Bastian Czogalla
Journal:  Cells       Date:  2020-05-15       Impact factor: 6.600

Review 7.  The Role of ABC Transporters in Lipid Metabolism and the Comorbid Course of Chronic Obstructive Pulmonary Disease and Atherosclerosis.

Authors:  Stanislav Kotlyarov; Anna Kotlyarova
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

8.  Antiretroviral Drug Transporters and Metabolic Enzymes in Circulating Monocytes and Monocyte-Derived Macrophages of ART-Treated People Living With HIV and HIV-Uninfected Individuals.

Authors:  Tozammel M D Hoque; Amélie Cattin; Sana-Kay Whyte-Allman; Lee Winchester; Courtney V Fletcher; Jean-Pierre Routy; Petronela Ancuta; Reina Bendayan
Journal:  J Acquir Immune Defic Syndr       Date:  2021-08-01       Impact factor: 3.771

9.  Polarized macrophage subsets differentially express the drug efflux transporters MRP1 and BCRP, resulting in altered HIV production.

Authors:  Hui He; Merrion Buckley; Bernard Britton; Ying Mu; Kristin Warner; Santosh Kumar; Theodore J Cory
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

10.  Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages.

Authors:  Yuqing Gong; Pallabita Chowdhury; Narasimha M Midde; Mohammad A Rahman; Murali M Yallapu; Santosh Kumar
Journal:  Biochem Biophys Rep       Date:  2017-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.